155 results about "Posaconazole" patented technology

The present invention provides formulations useful for treating infections, in particular, formulations that include the active pharmaceutical ingredient Posaconazole in an injectable suspension of particles that is stable when subjected to terminal sterilization. Preferred median particle sizes of between 1.5 and 3.0 microns are found to result in superior pharmacokinetic characteristics, such as those displayed below.

The invention discloses a method for preparing 1-(4-hydroxyphenyl)-4-(4-aminophenyl)piperazine intermediate. The piperazine intermediate has a structural formula II. The compound is a main intermediate of a novel medicament posaconazole for treating invasive fungal infection.

The invention provides novel soluble conazole crystalline forms (e.g. itraconazole, posaconazole and saperconazole) that include salts, co-crystals and related solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, these conazole crystalline forms. Methods of using such compositions for the treatment or prevention of systemic and local fungal, yeast, and dermatophyte infections are also provided.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug contraindicated for concomitant administration with a strong CYP3A4 inhibitor, wherein the patient is treated with multiple doses of posaconazole, stops posaconazole treatment, and then is treated with the CYP3A4 substrate drug. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-21 after stopping posaconazole. In some embodiments, the patient is treated with or prescribed a reduced dose of the CYP3A4 substrate drug for about 2-21 after stopping posaconazole.

The present application provides novel compositions comprising posaconazole and a polymer wherein the composition has a glass transition temperature (Tg) of less than about 1100 C. The application also describes compositions comprising posaconazole and a polymer having a bulk density of greater than about 0.4 mg/mL. The application also describes compositions comprising posaconazole and a polymer which provide an exposure (AUCtf) of at least about 10,000 ng·hr/mL when administered to a patient in a fasted state. The application also describes a novel process for preparing these compositions. The preff erred polymer is HPMCAS. Preferably the composition is an extruded material.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

The invention belongs to the medicine pharmacy field, and relates to a preparation method of posaconazole, which comprises the following steps: adding a compound in a formula (II) in an aprotic solvent for stirring and dissolving, adding an alkaline aqueous solution, and adding a compound in a formula (III) for reacting to obtain an intermediate compound in a formula (IV); reacting a compound in a formula (IV) and hydrochloric acid to obtain a compound crude product in a formula (I); and performing recrystallization by a mixed solvent of acetone/methanol. The method of the invention has the advantages that the operation is safe, the reaction is simple, the post-treatment is convenient, and the method is suitable for industrial production.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

The present invention provides formulations useful for treating infections, in particular, formulations that include the active pharmaceutical ingredient posaconazole in an injectable suspension that is stable when subjected to terminal steam sterilization.

The present invention relates to a delayed release composition comprising Posaconazole dissolved or molecularly dispersed in a polymer other than a hydroxypropyl methylcellulose derived polymer; wherein the composition is prepared by hot melt extruding an admixture of Posaconazole and the polymer. The present invention also provides a process of preparing said composition.

The present invention provides a solid molecularly dispersed composition comprising a poorly water soluble and weakly basic azole antifungal compound and a pH sensitive polymer, pharmaceutical compositions, comprising the solid molecularly dispersed composition of the invention and methods of treating and/or preventing a fungal infection in a patient in need thereof comprising orally administering a pharmaceutical composition comprising a composition of the invention to a patient in need thereof. Preferably the antifungal, compound is posaconazole, and the pH sensitive polymer is HPMCAS.

The invention belongs to the field of a medicinal preparation and specifically relates to a posaconazole solid dispersion and a preparation method of the solid dispersion and drug use. The invention provides a posaconazole solid dispersion and its drug use. The posaconazole solid dispersion contains posaconazole, a cyclodextrin derivative and a water-soluble or enteric carrier material, wherein mass ratio of posaconazole to the cyclodextrin derivative is 1:1-4 or mass ratio of posaconazole to the cyclodextrin derivative to the water-soluble or enteric carrier material is 1:1-4:0.001-3. The posaconazole solid dispersion can remarkably raise dissolution rate of the difficultly-soluble antifungal agent posaconazole in the small intestine and also can significantly enhance bioavailability of posaconazole. By the use of a dosage form prepared from the solid dispersion, the preparation technology is simple, and quality of the dosage form is stable.

The invention relates to a freeze-drying composition of a posaconazole prodrug and a preparation method and application of the freeze-drying composition of the posaconazole prodrug. The freeze-drying composition has the advantages that the freeze-drying composition is high in water solubility, and safety of the freeze-drying composition is guaranteed due to the fact that cyclodextrins auxiliary materials need not to be added during the preparation of the freeze-drying composition; the freeze-drying composition is suitable for being used for treating various amphotericin-intolerant or refractory adult invasive fungal infections; the freeze-drying composition is used as a preventive drug for high-risk patients, the freeze-drying composition is applicable to patients above 13 years old and with impaired immunity and especially applicable to patients who have graft versus host disease (GVHD) after hematopoietic stem cell transplant, patients with leukemia and patients with long-term leukopenia due to chemotherapy; compared with control drugs such as fluconazole and itraconazole, the freeze-drying composition can effectively prevent invasive aspergillosis and can lower the mortality related to the invasive fungal infections.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug contraindicated for concomitant administration with a strong CYP3A4 inhibitor, wherein the patient is treated with multiple doses of posaconazole, stops posaconazole treatment, and then is treated with the CYP3A4 substrate drug. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-21 after stopping posaconazole. In some embodiments, the patient is treated with or prescribed a reduced dose of the CYP3A4 substrate drug for about 2-21 after stopping posaconazole.

The invention provides novel soluble conazole crystalline forms (e.g. itraconazole, posaconazole and saperconazole) that include salts, co-crystals and related solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, these conazole crystalline forms. Methods of using such compositions for the treatment or prevention of systemic and local fungal, yeast, and dermatophyte infections are also provided.

The invention provides an antifungal medicament solid dispersion, and in particular relates to a posaconazole solid dispersion dispersed in a polymer skeleton. The polymer skeleton comprises two polymers, a first polymer can realize uniform dispersion or molecular dispersion of posaconazole in the polymer skeleton, and a second polymer can construct a microenvironment for improving the dissolution rate of posaconazole in an aqueous environment. Further, the polymer skeleton preferably comprises Soluplus and EudragitE100 in the weight ratio of 1:1.5-4. The posaconazole solid dispersion provided by the invention has good stability, good solubility in the gastrointestinal tract, and high bioavailability.

The invention belongs to the technical field of pharmacy, and specifically relates to a posaconazole solid dispersion and a preparation method thereof. The invention discloses a posaconazole solid dispersion which is composed of posaconazole and a water-soluble polymer according to a weight ratio of 1:0.5-10, and a pharmaceutical composition comprising the same. The provided posaconazole solid dispersion can prominently improve the dissolution rate of antifungal agent posaconazole, which is hard to dissolve, in small intestines, and is capable of prominently increasing the biological utilization rate of posaconazole. The pharmaceutical dosage forms prepared from the pharmaceutical composition comprising the provided solid dispersion has the advantages of simple preparation technology and stable quality.

The invention discloses a method for detecting posaconazole chiral isomers through high performance liquid chromatography. The method has the advantages that chromatographic columns filled with silica-gel-surface covalent bonding polysaccharide derivatives are adopted, double moving phases, namely a moving phase A and a moving phase B, are used for gradient elution, the moving phase A is a binary moving phase, and the moving phase B is a ternary moving phase, so that separation effect is good, and the method is simple, convenient and easy to operate; test results prove that posaconazole and the chiral isomers thereof can be well separated under the chromatographic conditions, and quality of bulk drugs of the posaconazole is controlled better.

The invention discloses a preparation method of posaconazole. The preparation method of the posaconazole provided by the invention comprises the following steps: in the presence of inorganic protonic acid, performing hydrolysis reaction on a compound II to obtain posaconazole I. The preparation method provided by the invention is easy and safe to operate, does not need any special equipment, is free from heavy metal residues, produces less reaction side products, and has high yield; a prepared product has high purity (chiral purity is larger than 99.90 percent, related substance purity is larger than 99.50 percent, all impurities are less than 0.1 percent, and raw materials meet the standard), is low in production cost, is environmentally friendly, and is suitable for industrial production. The formula of the posaconazole is shown in the description.